NCT05190146 is a clinical trial in Tuberculosis, Pulmonary, sponsored by Gates Medical Research Institute.

Who is sponsoring NCT05190146?

NCT05190146 is sponsored by Gates Medical Research Institute.

What condition does NCT05190146 study?

NCT05190146 studies Tuberculosis, Pulmonary.

Is NCT05190146 still recruiting?

NCT05190146 is currently completed. Last updated 13 December 2024.

Last reviewed 2024-12-13 · How we verify

NCT05190146

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epidemiologic Study to Assess the IGRA Positivity in Populations With a High TB Burden

Completed Last updated 13 December 2024

What this trial tests

trial in Tuberculosis, Pulmonary in 7,203 participants. Completed in 16 August 2024.

Timeline

20 December 2021

Primary endpoint
11 September 2023

16 August 2024

Quick facts

Lead sponsor	Gates Medical Research Institute
Status	Completed
Study type	OBSERVATIONAL
Enrollment	7,203
Start date	20 December 2021
Primary completion	11 September 2023
Estimated completion	16 August 2024
Sites	36 locations across South Africa, Uganda, Peru, Indonesia, Democratic Republic of the Congo, Vietnam, Zambia, Philippines

Conditions studied

Tuberculosis, Pulmonary — all drugs for Tuberculosis, Pulmonary →

Sponsor

Gates Medical Research Institute

Who can join

Adults 15 to 34, any sex, with Tuberculosis, Pulmonary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to conduct a multi-country, multi-site, epidemiologic study designed to assess the proportion of interferon gamma release assay (IGRA) positivity, at site level, and to build capacity to conduct a future TB vaccine efficacy study.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Interferon-gamma release assay positivity in populations at high risk of TB infection.
Dagnew AF, Han LL, Cinar A, Gaikwad D, et al · · 2026 · PMID 41994179 · DOI 10.5588/ijtldopen.25.0684
Driving innovation from discovery to access: Meeting report of the 7 <sup>th</sup> Global Forum on TB Vaccines (8-10 October 2024, Rio de Janeiro, Brazil).
Palmer S, Clark RA, Connell BJ, Muwanga VM, et al · · 2025 · PMID 40896556 · DOI 10.12688/gatesopenres.16360.1

Verify or expand the search:

Other recruiting trials for Tuberculosis, Pulmonary

Currently open trials in the same condition.

NCT07077213 — 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients · recruiting
NCT07271225 — Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting · NA · recruiting
NCT06845618 — Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment · recruiting
NCT06253715 — Shortened Regimen for Drug-susceptible TB in Children · Phase 3 · recruiting
NCT06057519 — Pragmatic Optimized Rifampicin Trial · Phase 3 · recruiting

Other Gates Medical Research Institute trials

Trials by the same sponsor.

NCT07517445 — Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susc · Phase 2 · not yet recruiting
NCT07525427 — Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis · Phase 2 · not yet recruiting
NCT07094932 — A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09 · Phase 1 · completed
NCT06707142 — A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11 · Phase 1 · completed
NCT05891236 — Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05190146 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gates Medical Research Institute
Last refreshed: 13 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05190146.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing